The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Randomized phase III trial comparing weekly docetaxel (D)-cisplatin (P) combination with triweekly D alone in elderly patients (pts) with advanced non-small cell lung cancer (NSCLC): An intergroup trial of JCOG0803/WJOG4307L.
T. Abe
No relevant relationships to disclose
A. Yokoyama
No relevant relationships to disclose
K. Takeda
No relevant relationships to disclose
Y. Ohe
Honoraria - Sanofi
S. Kudoh
No relevant relationships to disclose
Y. Ichinose
Honoraria - Sanofi
H. Okamoto
No relevant relationships to disclose
N. Yamamoto
No relevant relationships to disclose
H. Yoshioka
No relevant relationships to disclose
K. Minato
No relevant relationships to disclose
T. Sawa
No relevant relationships to disclose
Y. Iwamoto
No relevant relationships to disclose
H. Saka
No relevant relationships to disclose
J. Mizusawa
No relevant relationships to disclose
T. Shibata
No relevant relationships to disclose
S. Nakamura
No relevant relationships to disclose
M. Ando
No relevant relationships to disclose
K. Nakagawa
No relevant relationships to disclose
N. Saijo
No relevant relationships to disclose
T. Tamura
Honoraria - Bristol-Myers Squibb; Sanofi